Breaking News, Collaborations & Alliances

Wheeler Bio Licenses ATUM’s miFuc Platform for Afucosylated Antibodies

Provides clients with more options for their pharmaceutical development.

Author Image

By: Charlie Sternberg

Associate Editor

Wheeler Bio, Inc., a contract development and manufacturing organization (CDMO), is expanding its capabilities by licensing ATUM’s miFuc platform designed for expression of recombinant proteins containing afucosylated glycans.   ATUM’s miFuc technology is designed for the development of antibodies with significant reduction in fucosylation without affecting product titer, cellular growth rates, or incurring global glycan liabilities. Enabled by ATUM’s proprietary Leap-In Transposase technology...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters